BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £174.3m
Enterprise Value £112.7m
Revenue £12.6m
Position in Universe th / 1831

BRIEF-Bioinvent: Positive Interim Results From The Phase I/IIa Trial

Thu 28th January, 2021 6:51am
Jan 28 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT PHASE I/IIA DATA SUGGEST BI-1206 RESTORES
ACTIVITY OF
RITUXIMAB IN RELAPSED NON-HODGKIN'S LYMPHOMA PATIENTS
    * LONG-LASTING COMPLETE RESPONSES OBSERVED IN TWO
PATIENTSBEYOND
12 MONTHS
    * RESPONSES IN 6 OUT OF 9 PATIENTS EVALUATEDPROVIDE EXCITING
EVIDENCE THAT BI-1206 HAS POTENTIAL TO RESTORE ACTIVITY OF
RITUXIMAB IN NON-HODGKIN'S LYMPHOMA PATIENTS WHO HAVE RELAPSED
AFTER TREATMENT WITH RITUXIMAB
    * NO DOSE-LIMITING TOXICITIES HAVE BEEN OBSERVED IN FIVE
PATIENTS
WHO HAVE BEEN TREATED UNDER CURRENT PROTOCOL, DESPITE RECEIVING
HIGHER DOSES OF BI-1206

Source text for Eikon:  ID:nWkr9qPt3N 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.